Skip to content

Tango Therapeutics TNGX Common stock, shares issued (in shares)

Common stock, shares issued (in shares) at other companies

Gilead Sciences logo
Gilead SciencesGILD
Exelixis logo
ExelixisEXEL
Lantheus Holdings logo
Lantheus HoldingsLNTH
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Roivant Sciences logo
Roivant SciencesROIV
Guardant Health logo
Guardant HealthGH

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's common stock, shares issued (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tango Therapeutics's common stock, shares issued (in shares)?
Tango Therapeutics (TNGX) reported common stock, shares issued (in shares) of $144.16M in Q1 2026.
How has Tango Therapeutics's common stock, shares issued (in shares) changed year-over-year?
Tango Therapeutics's common stock, shares issued (in shares) increased by 33.4% year-over-year, from $108.11M to $144.16M.
What is the long-term trend for Tango Therapeutics's common stock, shares issued (in shares)?
Over 5 years (2020 to 2025), Tango Therapeutics's common stock, shares issued (in shares) has grown at a 27.5% compound annual growth rate (CAGR), from $40.37M to $135.94M.